Pharma executives don’t lose deals because they missed a clinical readout.
They lose them because they missed a patent map.
Eurasia—often treated as a “later” market—has become a high-stakes chessboard where drug patents, regulatory exclusivities, and …

Pharmaceutical patent strategy is often treated like a binary choice: fight for every right, or give up and move on.
But the real winners don’t “decide” in the abstract—they run a decision matrix.
In a recent DrugPatentWatch post, the core idea is simp…

The clock is already ticking. Most “market access” teams are just showing up after the race has started.
In pharma, timing isn’t a soft skill—it’s the business model.
Drug patent cliffs, exclusivity windows, and payer contracting cycles don’t wait for …

Before You Launch: The Hidden “Go/No-Go” Gate in Pharma—Freedom to Operate
In pharma, timelines are everything. But there’s a gate that can quietly derail even the most confident launch plan: Freedom to Operate (FTO).
Most teams treat FTO as a checkbox…

Pharma procurement teams are sitting on a blind spot—and it’s costing them leverage.
If you buy drugs, you already know the drill: negotiate price, pressure suppliers, validate quality, and keep formularies compliant. But there’s a quieter, higher-impa…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’ve ever modeled a product’s “time to generic” in Asia-Pacific, you’ve probably run into the same uncomfortable truth: patent life on paper doesn’…

Drug patent expiry dates aren’t just legal milestones—they’re commercial deadlines. And most companies treat them like back-office trivia instead of a growth strategy.
Here’s the agitation: when the market is moving, “we’ll revisit this later” is how y…

Sell the line before the patent breaks. That’s the playbook many pharma equipment suppliers are quietly adopting as the next wave of generic competition approaches. The old approach—waiting until a patent cliff is imminent, then pitching “new capacity”…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The smarter monopoly isn’t always the one you think.
Orphan drugs were built for a noble purpose: incentivize treatments for rare diseases where the market often won’t. But the policy mechanics behind orphan drug exclusivity—and how it stacks against…